Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Evidence for glucagon secretion and function within the human gut

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease

    Research output: Contribution to journalReviewpeer-review

  5. Chronic Kidney Disease-Induced Vascular Calcification Impairs Bone Metabolism

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIM: To investigate the effect of a glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide, on pancreatic volume, oedema, cellularity and DNA synthesis in humans.

MATERIALS AND METHODS: We performed an open-label study in 14 obese men (age 38 ± 11 years, body mass index 32 ± 4 kg/m 2 ) without diabetes. Subjects were examined at baseline, during titration (week 4) of liraglutide towards 3.0 mg/day, and 2 weeks after steady-state treatment (week 6) of a final dose of liraglutide. The primary endpoint was pancreatic volume determined by magnetic resonance imaging. Secondary endpoints included pancreatic oedema and cellularity, positron emission tomography-based [ 18 F]fluorothymidine (FLT) uptake (DNA synthesis) and plasma pancreatic enzymes.

RESULTS: Plasma amylase (+7 U/L [95% confidence intervals 3-11], P < .01) and lipase (+19 U/L [7-30], P < .01) increased during liraglutide treatment. Pancreatic volume did not change from baseline to steady state of treatment (+0.2 cm 3 [-8-8], P = .96) and no change in pancreatic cellular infiltration was found (P = .22). During titration of liraglutide, FLT uptake in pancreatic tissue increased numerically (+0.08 [0.00-0.17], P = .0507).

CONCLUSIONS: Six weeks of treatment with liraglutide did not affect pancreatic volume, oedema or cellularity in obese men without diabetes.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Volume22
Issue number10
Pages (from-to)1837-1846
Number of pages10
ISSN1462-8902
DOIs
Publication statusPublished - 1 Oct 2020

Bibliographical note

© 2020 John Wiley & Sons Ltd.

    Research areas

  • antiobesity drug clinical trial GLP-1 analogue

ID: 59999674